Page last updated: 2024-11-06

primuline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

primuline: a fluorescent terbenzothiazole; do not confuse with a malvidin anthocyanin which sometimes uses a similar name; transported retrogradely through axons to the neuronal soma [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

primuline : An organic sodium salt having 2'-(4-aminophenyl)-6-methyl[2,6'-bi-1,3-benzothiazole]-7-sulfonate as the counterion. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3769888
CHEMBL ID3974381
CHEBI ID90399
SCHEMBL ID95545
MeSH IDM0109111

Synonyms (25)

Synonym
primuline
10360-31-3
c.i. direct yellow 59, monosodium salt
nsc143368
primuline, dye content 50 %
P0603
sodium 2-[2-(4-aminophenyl)-1,3-benzothiazol-6-yl]-6-methyl-1,3-benzothiazole-7-sulfonate
einecs 233-781-3
(2,6'-bibenzothiazole)-7-sulfonic acid, 2'-(4-aminophenyl)-6-methyl-, sodium salt (1:1)
(2,6'-bibenzothiazole)-7-sulfonic acid, 2'-(4-aminophenyl)-6-methyl-, monosodium salt
sodium 2'-(4-aminophenyl)-6-methyl(2,6'-bibenzothiazole)-7-sulphonate
nsc 143368
[2,6'-bibenzothiazole]-7-sulfonic acid, 2'-(4-aminophenyl)-6-methyl-, monosodium salt
SCHEMBL95545
DTXSID1065051
sodium 2'-(4-aminophenyl)-6-methyl[2,6'-bibenzothiazole]-7-sulfonate
AKOS024370845
CHEMBL3974381
CHEBI:90399
sodium 2'-(4-aminophenyl)-6-methyl[2,6'-bi-1,3-benzothiazole]-7-sulfonate
mfcd00005798
sodium;2-[2-(4-aminophenyl)-1,3-benzothiazol-6-yl]-6-methyl-1,3-benzothiazole-7-sulfonate
Q7243701
sodium 2/'-(4-aminophenyl)-6-methyl[2,6/'-bibenzothiazole]-7-sulphonate
primuline ,

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Phototoxicity consists in the capability of certain innocuous molecules to become toxic when subjected to suitable illumination."( Reliable Screening of Dye Phototoxicity by Using a Caenorhabditis elegans Fast Bioassay.
Bianchi, JI; Blázquez-Castro, A; Buzz, LI; Buzzi, LI; Simonetta, SH; Stockert, JC, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
histological dyeA dye used in microscopic or electron microscopic examination of cells and tissues to give contrast and to highlight particular features of interest, such as nuclei and cytoplasm.
fluorochromeA fluorescent dye used to stain biological specimens.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
organic sodium salt
organosulfonate saltAny organic salt prepared using an organosulfonic acid as the acid component.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1330626Inhibition of Cy5-labeled dT15 DNA binding to Hepatitis C virus genotype 1b (con1) NS3 helicase DNA by fluorescence polarization assay2016European journal of medicinal chemistry, Nov-10, Volume: 123Computer-aided identification, synthesis and evaluation of substituted thienopyrimidines as novel inhibitors of HCV replication.
AID1330625Inhibition of protease domain lacking Hepatitis C virus genotype 1b (con1) C-terminal His-tagged NS3 helicase ATP hydrolysis activity using ATP as substrate preincubated followed by substrate addition measured after 15 mins in absence of poly U RNA by mal2016European journal of medicinal chemistry, Nov-10, Volume: 123Computer-aided identification, synthesis and evaluation of substituted thienopyrimidines as novel inhibitors of HCV replication.
AID1459836Inhibition of HCV NS3 helicase DNA unwinding activity using fluorescent DNA substrate by molecular beacon assay2017European journal of medicinal chemistry, Jan-05, Volume: 125In silico identification, design and synthesis of novel piperazine-based antiviral agents targeting the hepatitis C virus helicase.
AID1436686Inhibition of Hepatitis C virus genotype 1b NS3 helicase unwinding activity using fluorescent DNA substrate by molecular beacon assay2017Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4
Shape-based virtual screening, synthesis and evaluation of novel pyrrolone derivatives as antiviral agents against HCV.
AID1330624Inhibition of protease domain lacking Hepatitis C virus genotype 1b (con1) C-terminal His-tagged NS3 helicase ATP hydrolysis activity using ATP as substrate preincubated followed by substrate addition measured after 15 mins in presence of poly U RNA by ma2016European journal of medicinal chemistry, Nov-10, Volume: 123Computer-aided identification, synthesis and evaluation of substituted thienopyrimidines as novel inhibitors of HCV replication.
AID1330623Inhibition of Hepatitis C virus genotype 1b (con1) full length C-terminal His-tagged NS3 helicase expressed in Escherichia coli Rosette(DE3) assessed as inhibition of 5'-Cy5/3'-IAbRQ-labeled DNA unwinding activity by molecular beacon assay2016European journal of medicinal chemistry, Nov-10, Volume: 123Computer-aided identification, synthesis and evaluation of substituted thienopyrimidines as novel inhibitors of HCV replication.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (44.44)18.7374
1990's3 (11.11)18.2507
2000's3 (11.11)29.6817
2010's9 (33.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other31 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]